Fujian Shengdi Pharmaceutical: HRS9531 (Subsidiary of Jiangsu Hengrui Pharmaceutical) [59] [59] In a phase 1 study evaluating an oral GLP1R/GIP dual agonist, participants received subcutaneous injections of 8.1mg
AD: Alzheimers disease cAMP: cyclic adenosine monophosphate CSF: cerebrospinal fluid DPP-4: dipeptidyl-peptidase 4 DR: diabetic retinopathy GFAP: glial fibrillary acidic protein GLP-1: glucagon-like peptide 1 GLP-1R: glucagon-like peptide 1 receptor GLP-1RA: glucagon-like peptide 1 receptor agonist IIH: idiopathic intracranial hypertension IL-1beta: interleukin 1 beta NF-B: nuclear factor kappa B NO: nitric oxide PD: Parkinsons disease PINK1: protein phosphatase and tensin homolog-induced kinase 1 PKA: protein kinase A PPG: preproglucagon RGCs: retinal ganglion cells RPE: retinal pigment epithelium T2DM: type 2 diabetes mellitus TNF-alpha: tumor necrosis factor alpha VEGF: vascular endothelial growth factor Sohum S, AP, MF, MM, AR, RS, and Siddharth S: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writingoriginal draft
doi: 10.1038/nprot.2009.86 68 ChoiYChanAP
Yang, R
The net effects of the former reduce postprandial blood glucose, while the latter affects both fasting and postprandial blood glucose
